



COPY OF PAPERS
ORIGINALLY FILED

COPY OF PAPERS
ORIGINALLY FILED

1646 #6
June
6-6-02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Shelley E. Sakiyama-Elbert and Jeffrey A. Hubbell

RECEIVED

MAY 31 2002

TECH CENTER 1600/2900

Serial No.: 09/848,664

Art Unit: 1646

Filed: May 3, 2001

Examiner: Not Yet Assigned

For: *CONTROLLED RELEASE OF NON HEPARIN-BINDING GROWTH
FACTORS FROM HEPARIN-CONTAINING MATRICES*

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §1.56 and 37 C.F.R. §1.97, Applicants submit an Information Disclosure Statement, including seven (7) pages of Form PTO-1449. The documents cited below were cited by or submitted to the Patent Office in Application Serial No. 09/298,084, filed April 22, 1999, to which the present application claims priority. Pursuant to 37 C.F.R. §1.98(d), Applicants are not enclosing copies of these publications. Copies will be provided upon request, however.

This Information Disclosure Statement is being filed under 37 C.F.R. § 1.97(b) prior to a first Office Action on the merits. It is believed that no fee is required with this submission. However, should a fee be required, the Commissioner is hereby authorized to charge any required fees to Deposit Account No. 50-1868.

U.S. Patents

<u>Number</u>	<u>Issue Date</u>	<u>Patentee</u>
4,613,665	09-23-1986	Larm
4,810,784	03-07-1989	Larm
5,100,668	03-31-1992	Edelman et al.
5,693,341	12-02-1997	Shroeder et al.
5,830,700	11-03-1998	Irani

Publications

ALBERTS, et al., Molecular Biology of the Cell, Garland Publishing, New York, 1994.

BAGHERI-YAMAND, et al., *J Cancer* 78:111-118 (1998).

BESSON, et al., *Analytical Biochemistry* 237:216-223 (1996).

CAMARATA, et al., *Neurosurgery* 30:313-319 (1992).

CARDIN & WEINTRAUB, *Atherosclerosis* 9:21-32 (1989).

COOMBS, et al., *J Biol Chem* 237:4323-4328 (1998).

DE RAUCOURT, et al., *J Biomed Mater Res* 41:49-57 (1998).

DEBLOIS, et al., *Biomaterials* 15:665-672 (1994).

DINBERGS, et al., *J Biol Chem* 271(47):29822-29829 (1996).

DOWNS, et al., *Journal Cell Physiological* 152:422-429 (1992).

EDELMAN, et al., *Biomaterials* 12:619-626 (1991).

EDELMAN, et al., *Controlled Release Systems Containing Heparin and Growth Factors*, MIT: USA

EDELMAN, et al., *Proc Natl Acad Sci USA* 90:1513-1517 (1993).

EDELMAN, *Journal Clin Invest* 89:465-473 (1992).

GOTZ, et al., *Nature* 372:266-269 (1994).

HARADA, et al., *Journal Clin Invest* 94:623-630 (1994).

- HATA, et al., *J Biol Chem* 268:8847-8457 (1993).
- HAUGEN, et al., *J Neuroscience* 2034-2042 (1992).
- HERBERT, et al., *Journal Comp Neurological* 365:380-391 (1996).
- HIGASHIYAMA, et al., *Science* 251(4996):936-9 (1991).
- KALLAPUR, et al., *Journal of Neuroscience Research* 33:538-548 (1992).
- KANEDA, et al., *Journal Biochem* 119:1150-1156 (1996).
- KIGUCHI, et al., *Molecular Carcinogenesis* 22:73-83 (1998).
- KINOSAKI, et al., *Biochem Biophys Acta* 1384:93-102 (1998).
- LEE & LANDER, *Proc Natl Acad Sci USA* 88:2768-2772 (1991).
- LIN, et al., *Journal Neurochem* 63:758-768 (1994).
- LOPEZ, et al., *Drug Metabolism and Disposition* 24(8):922-924 (1996).
- LOPEZ, et al., *J Pharmacology and Experimental Therapeutics* 282(1):385-390 (1997).
- LYON, et al., *J Biol Chem* 272:1800-1806 (1997).
- MAAROUFI, et al., *Biomaterials* 18:359-366 (1997).
- MAYSINGER, et al., *Neurosci Lett* 140:71-74 (1992).
- MCCAFFREY, et al., *J Cellular Physiology* 152:430-440 (1992).
- NETZEL-ARNETT, et al., *J Biol Chem* 266:6747-6755 (1991).
- NOLO, et al., *European Journal of Neuroscience* 8:1658-1665 (1996).
- POWELL, et al., *Brain Res* 515:309-311 (1990).
- POWELL, et al., *Brain Research* 515:309-311 (1990).
- PRESTA, et al., *Biochem Biophys Res Commun* 185:1098-1107 (1992).
- REDDI, *Nature Biotechnology* 16:247-252 (1998).
- SCHENSE & HUBBELL, *Bioconjug Chem* 10:75-81 (1999).

SCHROEDER, et al., *Affinity Bound Collagen Matrices for the Delivery of Biologically Active Agents*, Collagen Corporation: USA (1997).

SELKE, et al., *Am J Physiol* 267:(Heart Circ Physiol. 36):H1303-H1311 (1994).

SHROEDER-TEFT, et al., *J Controlled Release* 48:29-33 (1997).

SILVER, et al., *Biomaterials* 13:339-344 (1992).

SMITH, et al., *J Biol Chem* 270:6440-6449 (1995).

SPILLMANN & LINDAHL, *J Biol Chem* 273:15487-15493 (1988).

STEFFEN, et al., *Growth Factors* 15:199-213 (1998).

STUDIER, et al., Expression in E. Coli, American Press, Inc. 61-89 (1990).

TAKAGI, et al., *Biochemistry* 14(23):5149-5156 (1975).

TESSLER, et la., *J Biol Chem* 269:12456-12461 (1994).

TYLER-CROSS, et al., *Protein Science* 3:620-627 (1994).

ZUCKER & KATZ, *Society for Experimental Biology and Medicine* pp. 693-702 (1991).

U.S.S.N.: 09/848,664
Filed: May 3, 2001
INFORMATION DISCLOSURE STATEMENT

Remarks

This statement should not be interpreted as a representation that an exhaustive search has been conducted or that no better art exists. Moreover, Applicants invite the Examiner to make an independent evaluation of the cited art to determine its relevance to the subject matter of the present application. Applicants are of the opinion that their claims patentably distinguish over the art referred to herein, either alone or in combination.

Respectfully submitted,



Patrea L. Pabst
Reg. No. 31,284

Dated: May 9, 2002


HOLLAND & KNIGHT LLP
One Atlantic Center
1201 West Peachtree Street, N.E.
Suite 2000
Atlanta, Georgia 30309-3400
404-817-8473
FAX 404-817-8588
www.hklaw.com

U.S.S.N.: 09/848,664
Filed: May 3, 2001
INFORMATION DISCLOSURE STATEMENT

Certificate of Mailing under 37 C.F.R. § 1.8(a)

I hereby certify that this Information Disclosure Statement, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Date: May 10, 2002


Kimberly L. Adams

ATL1 #522410 v1

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Completion if Known	
<p align="center">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p align="center">(Use as many sheets as necessary)</p> <div style="border: 1px solid black; border-radius: 50%; width: 150px; height: 150px; display: flex; align-items: center; justify-content: center; margin: 0 auto;"> <div style="writing-mode: vertical-rl; transform: rotate(180deg);"> OIPE MAY 28 2002 PATENT & TRADEMARK OFF. </div> </div>		Application Number	09/848,664
		Filing Date	May 3, 2001
		First Named Inventor	Shelly E. Sakiyama-Elbert
		Group Art Unit	1646
		Examiner Name	
		Attorney Docket Number	ETH 108 CON
Sheet	of	7	

[illegible][illegible]

Examine Signature		Date Considered	
-------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.